Physician profile
Robin A Lee
NPI 1700098100
$1,093.10
in general payments reported to CMS, 2019-2025
12 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $100 · 2021: $145 · 2022: $120 · 2024: $219 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $251.22 | 2019-2025 | Permeaderm, Recell, Cohealyx |
| Acera Surgical, INC. | $171.83 | 2024-2025 | Restrata Wound Matrix |
| Polynovo North America LLC | $165.98 | 2022-2025 | Novosorb Btm |
| Integra Lifesciences Corporation | $145.14 | 2021 | |
| Kerecis Limited | $118.87 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Chiesi USA, INC. | $62.27 | 2020 | |
| Urgo Medical North America, LLC | $52.19 | 2024 | Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Nevro Corp. | $38.10 | 2020 | |
| Vericel Corporation | $36.72 | 2025 | Nexobrid |
| Smith+Nephew, INC. | $21.74 | 2025 | Oasis, Collagenase Santyl, Versajet |
| Rare Disease Therapeutics, INC. | $15.00 | 2022 | |
| Csl Behring | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.